Contact Us

Follow

New age-related regenerative medicine

"Stem cell research is one of the most exciting frontiers for bioscience."

Bob Duggan

Overview

OxStem is developing new approaches to age-related regenerative medicine, focusing on drugs that can treat cancer, neurodegenerative diseases, ocular diseases, diabetes, heart disease, macular degeneration, chronic inflammation, wound healing, and other major age-related conditions.

OxStem aims to work with partners at Oxford University to use stem cells and medicinal chemistry to identify new classes of drugs that can re-program or stimulate endogenous cells, awakening previously defunct or dormant cellular processes.

The company is an Oxford University spinout, founded in 2014 by Professor Steve Davies, Professor Dame Kay Davies, Professor Angela Russell, and several angel investors based in Oxford, UK.  Bob Duggan has been an active investor through his associated interest in Human Longevity, Inc.

Technology

OxStem has formed a team with decades of experience in medicinal medicine. They are brilliantly aligning to design drugs that can “program resident stem and stem-like cells in situ to treat currently untreatable age-related conditions.”

OxStem Oncology is developing a universal differentiation therapy targeting hematological malignancies, focusing on acute myeloid leukemia (AML). The new medicine is expected to normalize hemopoiesis by differentiating leukemic myeloblasts resulting in complete durable remission for AML patients irrespective of their mutation status.

OxStem Ocular aims to identify new classes of drugs that can stimulate retinal precursor cells in patients with retinopathies such as dry age-related macular degeneration (dAMD) and retinitis pigmentosa. These new medicines are expected to induce retinal repair resulting in the restoration of vision.

OxStem Neuro has identified small molecules that can stimulate neural stem cells in situ resulting in neurogenesis and enhancement of cognitive function. As neurogenesis is compromised during aging and in neurodegenerative diseases such as Alzheimer’s, induction of neurogenesis represents a new therapeutic principle for such conditions.

OxStem Cardio aims to identify new classes of drugs that can stimulate cardiovascular cell regeneration from the activated epicardium and coronary lymphatic vessels. This is expected to restore lost tissue and improve cardiac function in cardiac disease conditions such as myocardial infarction.

OxStem Beta will develop therapeutics which stimulate regeneration of insulin-producing beta cells using small molecules diabetes.

OxStem Immuno’s underpinning technology aims to help stimulate tissue repair in chronic inflammation. The aim is to develop small molecules capable of switching macrophages from an infection-fighting anti-inflammatory phenotype, to treat chronic wounds such as diabetic foot ulcers.

Screening

 

Key Dates

OxStem appoints Dr. Ian Churcher as Chief Scientific Officer and announces further C-suite changes

06 Jan 2020

Go to link

OxStem appoints Chief Executive Officer

25 Mar 2019

Go to link

OxStem Beta and OxStem Immuno added to the portfolio of subsidiaries under the OxStem umbrella

04 Oct 2018

Go to link

Oxford Stem Cell Institute Symposium 2018 – “Stem Cells: From Mechanism to Therapy”

24 Sep 2018

Go to link

OxStem appoints Chief Scientific Officer

10 Sep 2018

Go to link

The cardiac lymphatic system stimulates resolution of inflammation following myocardial infarction – Prof. Paul Riley

26 Jul 2018

Go to link

Three Oxford researchers honoured by Royal Society

20 Jul 2018

Go to link

OxStem Presenting at Biotech Showcase, San Francisco

09 Jan 2018

Go to link

OxStem limited strengthens management team

09 Oct 2017

Go to link

Therapeutic developments: Masters of medicine

24 May 2017

Go to link

Record £16.9m for Oxford spinout designing stem cell drugs to treat age-related disease

10 May 2016

Go to link

Media

Now in development: off-the-shelf stem cells

27 Sep 2019

Go to link

9 Regenerative medicine companies for living longer

20 Feb 2019

Go to link

Oxford regenerative medicine spinout brings on GlaxoSmithKline drug hunter as CSO

10 Sep 2018

Go to link

These are the best tech startups from Oxford University Innovation

27 Nov 2017

Go to link

Oxford biotech deals highlight stature of UK university spinouts

10 May 2016

Go to link

" OxStem...was founded with the goal of treating age-related diseases by regulating stem cells with small-molecule compounds."

Nature

17 May 2017

Key Dates

OxStem appoints Dr. Ian Churcher as Chief Scientific Officer and announces further C-suite changes

06 Jan 2020

OxStem appoints Chief Executive Officer

25 Mar 2019

OxStem Beta and OxStem Immuno added to the portfolio of subsidiaries under the OxStem umbrella

04 Oct 2018

Oxford Stem Cell Institute Symposium 2018 – “Stem Cells: From Mechanism to Therapy”

24 Sep 2018

OxStem appoints Chief Scientific Officer

10 Sep 2018

The cardiac lymphatic system stimulates resolution of inflammation following myocardial infarction – Prof. Paul Riley

26 Jul 2018

Three Oxford researchers honoured by Royal Society

20 Jul 2018

OxStem Presenting at Biotech Showcase, San Francisco

09 Jan 2018

OxStem limited strengthens management team

09 Oct 2017

Therapeutic developments: Masters of medicine

24 May 2017

Record £16.9m for Oxford spinout designing stem cell drugs to treat age-related disease

10 May 2016

Media

Now in development: off-the-shelf stem cells

27 Sep 2019

9 Regenerative medicine companies for living longer

20 Feb 2019

Oxford regenerative medicine spinout brings on GlaxoSmithKline drug hunter as CSO

10 Sep 2018

These are the best tech startups from Oxford University Innovation

27 Nov 2017

Oxford biotech deals highlight stature of UK university spinouts

10 May 2016